Recall of AxSYM® Anti-TPO

According to L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), this recall involved a device in France that was produced by ABBOTT.

What is this?

A correction or removal action taken by a manufacturer to address a problem with a medical device. Recalls occur when a medical device is defective, when it could be a risk to health, or when it is both defective and a risk to health.

Learn more about the data here
  • Type of Event
  • Date
  • Event Country
  • Event Source
  • Event Source URL
  • Notes / Alerts
    French data is current through early September 2018. All of the data comes from L’Agence nationale de sécurité du médicament et des produits de santé (ANSM), except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and France.
  • Extra notes in the data
  • Action
    On 30 June 2005, ABBOTT France withdrew from the market lot 22827HN00 (per 12/09/2005) of the in vitro diagnostic medical device known as AxSYM® Anti-TPO reference 5F57-20. This decision follows the identification of an error during the final manufacturing phase of this lot. Indeed, the AxSYM Anti-TPO assay diluent (reagent 3) has been erroneously replaced by another solution in some of the packs of this lot. This device is used for the quantitative measurement of IgG autoantibodies directed against thyroperoxidase (anti-TPO) in human serum or plasma. It is an aid for the diagnosis of thyroid diseases .. The company has directly notified the recipients of the offending lot by means of the attached message (30/06/2005) (88 KB) validated by Afssaps .. This information s address to laboratory managers, directors of health establishments and reactive vigilance correspondents for dissemination, where appropriate, to the services concerned.


  • Model / Serial
  • Product Description
  • Manufacturer


  • Manufacturer Parent Company (2017)
  • Manufacturer comment
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source